IP Verse

Rapid Dissolution Formulation Of A Cinacalcet Hcl - EP3395339

The patent EP3395339 was granted to Amgen on Dec 11, 2019. The application was originally filed on Sep 10, 2004 under application number EP18175497A. The patent is currently recorded with a legal status of "Revoked".

EP3395339

AMGEN
Application Number
EP18175497A
Filing Date
Sep 10, 2004
Status
Revoked
Oct 14, 2022
Grant Date
Dec 11, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXALDec 23, 2020VOSINTERVENTION ADMISSIBLE
BETAPHARM ARZNEIMITTELDec 9, 2020HAMM & WITTKOPPINTERVENTION ADMISSIBLE
AECHTERJan 17, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
BIOGARANJan 17, 2020CASALONGAADMISSIBLE
MAIWALDJan 17, 2020-ADMISSIBLE
ZENTIVAJan 17, 2020ELLISADMISSIBLE
ACCORD HEALTHCAREJan 17, 2020TER MEER STEINMEISTER & PARTNERWITHDRAWN
GILLARDJan 16, 2020ELKINGTON AND FIFEADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPEJan 16, 2020SCHLICHADMISSIBLE
HGFJan 16, 2020-ADMISSIBLE
TEVA PHARMACEUTICALSJan 13, 2020ELKINGTON AND FIFEWITHDRAWN

Patent Citations (34) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0933354
DESCRIPTIONUS2002107406
DESCRIPTIONUS5981599
DESCRIPTIONUS6001884
DESCRIPTIONUS6011068
DESCRIPTIONUS6031003
DESCRIPTIONUS6172091
DESCRIPTIONUS6211244
DESCRIPTIONUS6313146
DESCRIPTIONUS6342532
DESCRIPTIONUS6363231
DESCRIPTIONUS6432656
DESCRIPTIONWO0134562
DESCRIPTIONWO9304373
DESCRIPTIONWO9418959
DESCRIPTIONWO9511221
DESCRIPTIONWO9612697
DESCRIPTIONWO9741090
OPPOSITIONEP1663182
OPPOSITIONEP2316442
OPPOSITIONEP2821067
OPPOSITIONEP3260117
OPPOSITIONEP3395338
OPPOSITIONEP3395339
OPPOSITIONEP3395340
OPPOSITIONEP3578175
OPPOSITIONUS6211244
OPPOSITIONUS6313146
OPPOSITIONUS6596311
OPPOSITIONUS9375405
OPPOSITIONWO03086343
OPPOSITIONWO2005034928
SEARCHUS6211244
SEARCHUS6313146

Non-Patent Literature (NPL) Citations (73) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BERGE et al., J. Pharm. Sci., (19770000), vol. 66, page 1-
OPPOSITION- "15.7 Polyvinylpyrrolidon, quervernetzt", P. C. Schmidt, Tubingen et al, Wirk- und Hilffsstofffe fiir Rezeptur, Defektur und GroBherstellunq, (1999), page 267, XP055784967-
OPPOSITION- "1 Preformulation Testing", LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets volume 1, (19890000), pages 1 - 73, XP009184711-
OPPOSITION- Ainley Wade, Paul J. Weller, Handbook of Pharmaceutical Excipients, Second Edition, American Pharmaceutical Association, (19940000), pages 483 - 493, XP055671886-
OPPOSITION- A. LE HIR, "Abrégé de pharmacie galénique formes pharmaceutiques", Abrégé de pharmacie galénique formes pharmaceutiques,, (19810000), pages 94-95,104 - 105,204-209,205-255, XP055673484-
OPPOSITION- Alfonso R. Gennaro, "Oral Solid Dosage Forms", REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, (20000101), pages 704 - 858-893, XP055673423-
OPPOSITION- Alfonso R. Gennaro, "Oral Solid Dosage Forms", REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, (20000101), vol. 704, pages 858 - 893, XP055673423-
OPPOSITION- "Amgen Submitted New Drug Application for Cinacalcet HC1", Amgen News Release, (20030908), XP055674150-
OPPOSITION- ANONYMOUS, "Amgen submitted new drug application for Cinacalcet HCI", AMGEN NEWS RELEASE, (20030908), URL: http://www.amgen.com/news/n ews03/pressRelease030908a. pdf, (20050112), XP002313388-
OPPOSITION- Anonymous, "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", ClinicalTrials.gov /NCT00042653/, (20020806), URL: https://clinicaltrials.gov/ct2/show/NCT00042653, XP055671896-
OPPOSITION- Anonymous, "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", ClinicalTrials.gov /NCT00042653/, ClinicalTrials.gov /NCT00042653/, URL: https://clinicaltrials.gov/ct2/show/NCT00042653, (20200226), XP055671896-
OPPOSITION- Anonymous, "Chemistry Review(s)", Center for Drug Evaluation and Research Application Number: 21-688, (2004), page 22pp, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Chemr.pdf, XP055671894-
OPPOSITION- Anonymous, "Chemistry Review(s)", Center for Drug Evaluation and Research Application Number: 21-688, page 22pp, Center for Drug Evaluation and Research Application Number: 21-688, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Chemr.pdf, (20200226), XP055671894-
OPPOSITION- Anonymous, "Clinical Pharmacology and Biopharmaceutics Review. Application Number 21-688", Center for Drug Evaluation and Research, (20030905), pages 1 - 53, XP055673474-
OPPOSITION- Anonymous, "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations", U.S. Food and Drug Administration /FDA/, URL: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021688&Appl_type=N-
OPPOSITION- Anonymus, "Chapter 18: Tablets", Pharmaceutics: The Science of Dosage Form Design, (19880000), pages 304 - 305, XP055673010-
OPPOSITION- Anonymus, "Clinical Pharmacology and Biopharmaceutics Review. Application Number 21-688", Center for Drug Evaluation and Research, (20030905), pages 1 - 53, XP055673474-
OPPOSITION- Anonymus, Pharmaceutics: The Science of Dosage Form Design, (20020000), pages 404 - 408, XP055673015-
OPPOSITION- AULTON, "Dosage form design and manufacture", Pharmaceutics: The Science of Dosage Form Design, (20020000), pages 404 - 408, XP055673015-
OPPOSITION- AULTON M.E, Pharmaceutics: The Science of Dosage Form Design, New York, (19880000), pages 311 - 312, XP055673027-
OPPOSITION- A. Wade et al, "Microcrystalline Cellulose / Crospovidone / Pregelatinized Starch", Handbook of pharmaceutical excipients, 2nd ed, (19940101), pages 84-87 - 143-144 491- 493, XP055673621-
OPPOSITION- CHAPTER16, CHAPTER16, Hans Leuenberger,, Martin . Fhysikafedte Pharmasie, (2002), pages 656 - 662, XP055784935-
OPPOSITION- "CHAPTER4", RITSCHEL W A, RITSCHEL W A Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung,, (2002), pages 268 - 277, XP055274661-
OPPOSITION- "Compressed Tablets by Wet Granulation", LibermanH ET AL, Pharmaceutical Dosage Forms, (1989), pages 92,149 - 150, XP055784979-
OPPOSITION- "crospovidone", Raymon C Rowe et al, Handbook of pharmaceutical excipients, (2006), XP055784959-
OPPOSITION- Deodatt A Wadke, "Chapter 1 - Preformulation Testing", Deodatt A Wadke, LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets, Volume 1, 2nd ed,, (19890000), pages 1 - 24, XP055416092-
OPPOSITION- Eugene F. Fiese et al, "Preformulation", The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870101), pages 171 - 303, XP055671875-
OPPOSITION- Eugene F. Fiese, Timothy A. Hagen, "Preformulation", Eugene F. Fiese, Timothy A. Hagen, Leon Lachman, Herbert A Lieberman and Joseph L Kanig, The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870000), pages 171-197, 298 - 303, XP055671875-
OPPOSITION- Eugene F. Fiese, Timothy A. Hagen, "Preformulation", The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870101), pages 171-197 - 298-303, XP055671875-
OPPOSITION- Fda, "Drug approval Package: Sensipar (Cinacalcet HCI) NDA #021688", URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm, (20200304), XP055673613-
OPPOSITION- Gennaro et al., "Chapter 45 - Oral Solid Dosage Forms", Remington: The Science and Practice of Pharmacy, (2000), pages 858 - 893, XP055301374-
OPPOSITION- GIBALDI, "Gastrointestinal Absorption - Physicochemical Considerations", Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, (19910000), page 51, XP055282823-
OPPOSITION- GIBALDI, GIBALDI, Milo Gibaldi, Biopharmaceutics and Clinical Pharmacokinetics, fourth edition,, Lea& Febiger, (19910000), vol. 2pp, 51, XP055282823-
OPPOSITION- GOODMAN WILLIAM G et al., "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY: JASN. APR 2002, (20020400), vol. 13, no. 4, ISSN 1 046-6673, pages 1017 - 1024, XP002313387-
OPPOSITION- GOODMAN WILLIAM G et al., "The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism", Journal of the American Society of Nephrology, vol. 13, no. 4, pages 1017 - 1024, XP002387352-
OPPOSITION- J.C CHAUMEIL, "Micronisation : a method for improving the bioavailability of poorly soluble drugs", Meth Find Clin. Pharmacol, (19980000), pages 211 - 215, XP055673475-
OPPOSITION- Joseph P. Remington, "Dissolution", Joseph P. Remington, Gennaro Alfonso R., Remington: the science and practice of pharmacy, Easton, Pennsylvania, Mack Publishing Company, (19950101), page 2pp, 595, ISBN 978-0-912734-04-0, XP055282825-
OPPOSITION- Karande, A.D. ; Heng, P.W.S. ; Liew, C.V., "In-line quantification of micronized drug and excipients in tablets by near infrared (NIR) spectroscopy: Real time monitoring of tabletting process", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (20100830), vol. 396, pages 63 - 74, XP027169573-
OPPOSITION- Kathleen M Lee, "Unit 7.3: Overview of Drug Product Development", Current Protocols in Pharmacology, (20010000), pages 7.3.1 - 7.3.10, XP055319345-
OPPOSITION- Kathleen M. Lee, "Unit 7.3: Overview of Drug Product Development", Current Protocols in Pharmacology, (20010101), pages 7.3.1 - 7.3.10, XP055319345-
OPPOSITION- KLANCKE J, "Dissolution Testing of Orally Disintegrating Tablets", DISSOLUTION TECHNOLOGIES, (20030000), pages 6 - 8, XP002545423-
OPPOSITION- "Lactose-MonohydratLactosum monohydricum", Kommentar zur Ph. Eur. 9.0, (2017), pages 1 - 5, XP055784984-
OPPOSITION- Leon Lachman, Et Al, "The Theory and Practice of Industrial Pharmacy, third edition", The Theory and Practice of Industrial Pharmacy, third edition, Lea & Febiger, (19860101), pages 189, 321 - 324-329, XP055673418-
OPPOSITION- Lieberman Herbert A. et al, Pharmaceutical Dosage Forms, Chapters 3 and 4, New York, Basel, Hong Kong, Marcel Dekker Inc., (19900000), vol. 1-
OPPOSITION- LIEBERMAN HERBERT A. ET AL: "Pharmaceutical Dosage Forms, Chapters 3 and 4", vol. 1, 1990, MARCEL DEKKER INC., New York, Basel, Hong Kong-
OPPOSITION- L. LACHMAN et al., The theory and Practice of Industrial Pharmacy, (19860000), pages 324 - 328, XP055673018-
OPPOSITION- "Magnesiumstearat", Magnesiumstearat-
OPPOSITION- MICHAEL AULTON, "Factors influencing bioavailability: factors influencing drug absorption from the gastrointestinal tract", PHARMACEUTICS :THE SCIENCE OF DOSAGE FORM DESIGN,, (19880000), pages 135,156 - 157, XP055673473-
OPPOSITION- Michael E. Aulton, Pharmaceutics: The Science of Dosage Form Design, Second Edition, Spain, Elsevier, (20020000), pages 113-138, 397 - 440, XP055671888-
OPPOSITION- Milo Gibaldi, "Biopharmaceutics and Clinical Pharmacokinetics, fourth edition", Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, Lea& Febiger, (19910101), page 2pp, 51, ISBN 978-0-8121-1346-4, XP055282823-
OPPOSITION- Raymond C. Rowe et al, "Cellulose, Microcrystalline / Starch", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS, (20030529), pages 108-111 - 603-611, XP055673426-
OPPOSITION- Raymond C. Rowe et al, "Cellulose, Microcrystalline / Starch", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS, (20030529), pages 108 - 603-611, XP055673426-
OPPOSITION- Raymond C Rowe et al, "Croscarmellose sodium", Handbook of Pharmaceutical Excipients, (2006), pages 211-216 ,702 - 704, XP055784136-
OPPOSITION- Raymond C Rowe Et Al.,, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Sixth Edition, Pharmaceutical Press, (20090000), pages 2pp, 129-131,185,186,208,404,581,582,691 - 692, XP055671872-
OPPOSITION- Remington - The Science and Practice of Pharmacy, (20000000), vol. 1, page 862, XP055673031-
OPPOSITION- RITSCHEL et al., "Die Tablette", (20020000), pages 332 - 335, XP55673487-
OPPOSITION- Rudolf Voigt, "Tabletten", PHARMAZEUTISCHE TECHNOLOGIE : FÃœR STUDIUM UND BERUF, Stuttgart, Deutscher Apotheker Verlag, (20000101), pages 163 - 187, XP055673408-
OPPOSITION- U. V. Banakar, "Factors That Influence Dissolution Testing", Pharmaceutical Dissolution Testing, (19920101), pages 136 - 145, ISBN 978-0-8247-8567-3, XP055308585-
OPPOSITION- Wolfgang A. Ritschel, Die Tablette, Handbuch der Entwicklung, Herstellung und Qualitätssicherung, 2. Auflage, Editio Cantor Verlag Aulendorf, (20020000), pages 332 - 335, XP055673487-
OPPOSITION- L. D. Quarles, et al.,, "The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease", Journal of the American Society of Nephrology, (20030000), vol. 14, pages 575 - 583, XP055671891
OPPOSITION- QUARLES, L.D. et al., "The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease", Am Soc Nephrol, (20030300), vol. 14, pages 575 - 583, XP055671891
OPPOSITION- "Super Disintegrants: Characterization and Function", Swarbrick J; Et Al, Encyclopaedia of Pharmaceutical Technology. Vol 20,, Marcel Dekker, (2001), pages 269 - 293, XP055512903
OPPOSITION- Swarbrick J. et al, "Super Disintegrants: Characterization and Function", Encyclopaedia of Pharmaceutical Technology, Marcel Dekker, (20010101), vol. 20, pages 269 - 293, XP055512903
OPPOSITION- FRANCE SCHINI et al., "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin Investig Drugs, (20030000), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 21, XP009083254
OPPOSITION- FRANCE SCHINI, N et al., "Cinacalcet HC1 : a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert opin. Investig. Drugs, (20030000), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCESCHINI N; ET AL, "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opinion on Investigational Drugs, (20030000), doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCESCHINI N. et al, "CINACALCET HCI: A CALCIMIMETIC AGENT FOR THE MANAGEMENT OF PRIMARY AND SECONDARY HYPERPARATHYROIDISM", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK, (20030101), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, ISSN 1354-3784, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCESCHINI N. et al, "CINACALCET HCI: A CALCIMIMETIC AGENT FOR THE MANAGEMENT OF PRIMARY AND SECONDARY HYPERPARATHYROIDISM", Expert Opinion on Investigational Drugs, UK, (20030101), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, ISSN 1354-3784, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCESCHINI N; JOY M S; KSHIRSAGAR A, "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin Investig Drugs, (20030812), vol. 12, no. 8, pages 1413 - 1421, XP009083254
OPPOSITION- GISSINGER D; STAMM A, "A Comparative Evaluation of the Properties of some Tablet Disintegrants", Drug Development and Industrial Pharmacy, (19800000), vol. 6, no. 5, pages 511 - 536, XP008063508
SEARCH- ANONYMOUS, "Amgen submitted new drug application for Cinacalcet HCI", (20030908), AMGEN NEWS RELEASE, URL: http://www.amgen.com/news/news03/pressRelease030908a.pdf, (20050112), XP002313388 [Y] 1-15 * the whole document *-
SEARCH- ANONYMOUS, "NPS-Drug Development: Product Develpment Pipeline", (20030908), INTERNET ARTICLE, URL: www.npsp.com/drug_development/pipeline.php, (20050112), XP002313391 [A] 1-15 * the whole document *-
SEARCH- GOODMAN WILLIAM G ET AL, "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN. APR 2002, (200204), vol. 13, no. 4, ISSN 1046-6673, pages 1017 - 1024, XP002313387 [Y] 1-15 * the whole document *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents